Sweat Metabolomics Before and After Intravenous Antibiotics for Pulmonary Exacerbation in People with Cystic Fibrosis

Overview

Journal Respir Med

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2021 Dec 5

PMID 34864373

Citations 3

Authors

Frederick W Woodley

Emrah Gecili

Rhonda D Szczesniak

Chandra L Shrestha

Christopher J Nemastil

Benjamin T Kopp

Don Hayes Jr

Affiliations

Soon will be listed here.

Abstract

Background: People with cystic fibrosis (PWCF) suffer from acute unpredictable reductions in pulmonary function associated with a pulmonary exacerbation (PEx) that may require hospitalization. PEx symptoms vary between PWCF without universal diagnostic criteria for diagnosis and response to treatment.

Research Question: We characterized sweat metabolomes before and after intravenous (IV) antibiotics in PWCF hospitalized for PEx to determine feasibility and define biological alterations by IV antibiotics for PEx.

Study Design And Methods: PWCF with PEx requiring hospitalization for IV antibiotics were recruited from clinic. Sweat samples were collected using the Macroduct® Sweat Collection System at admission prior to initiation of IV antibiotics and after completion prior to discharge. Samples were analyzed for metabolite changes using ultra-high-performance liquid chromatography/tandem accurate mass spectrometry.

Results: Twenty-six of 29 hospitalized PWCF completed the entire study. A total of 326 compounds of known identity were detected in sweat samples. Of detected metabolites, 147 were significantly different between pre-initiation and post-completion of IV antibiotics for PEx (average treatment 14 days). Global sweat metabolomes changed from before and after IV antibiotic treatment. We discovered specific metabolite profiles predictive of PEx status as well as enriched biologic pathways associated with PEx. However, metabolomic changes were similar in PWCF who failed to return to baseline pulmonary function and those who did not.

Interpretation: Our findings demonstrate the feasibility of non-invasive sweat metabolomic profiling in PWCF and the potential for sweat metabolomics as a prospective diagnostic and research tool to further advance our understanding of PEx in PWCF.

Citing Articles

Critical Factors in Sample Collection and Preparation for Clinical Metabolomics of Underexplored Biological Specimens.

de Souza H, Pereira T, de Sa H, Alves M, Garrett R, Canuto G Metabolites. 2024; 14(1).

PMID: 38248839 PMC: 10819689. DOI: 10.3390/metabo14010036.

Enrichment of sweat-derived extracellular vesicles of human and bacterial origin for biomarker identification.

Zhyvolozhnyi A, Samoylenko A, Bart G, Kaisanlahti A, Hekkala J, Makieieva O Nanotheranostics. 2024; 8(1):48-63.

PMID: 38164498 PMC: 10750121. DOI: 10.7150/ntno.87822.

Changes in fecal lipidome after treatment with ivacaftor without changes in microbiome or bile acids.

Bass R, Tanes C, Bittinger K, Li Y, Lee H, Friedman E J Cyst Fibros. 2023; 23(3):481-489.

PMID: 37813785 PMC: 10998923. DOI: 10.1016/j.jcf.2023.09.010.

References

Muhlebach M, Sha W . Lessons learned from metabolomics in cystic fibrosis. Mol Cell Pediatr. 2015; 2(1):9. PMC: 4883209. DOI: 10.1186/s40348-015-0020-8. View

Wheelock C, Strandvik B . Abnormal n-6 fatty acid metabolism in cystic fibrosis contributes to pulmonary symptoms. Prostaglandins Leukot Essent Fatty Acids. 2020; 160:102156. DOI: 10.1016/j.plefa.2020.102156. View

Hammond K, Turcios N, Gibson L . Clinical evaluation of the macroduct sweat collection system and conductivity analyzer in the diagnosis of cystic fibrosis. J Pediatr. 1994; 124(2):255-60. DOI: 10.1016/s0022-3476(94)70314-0. View

Sanders D, Bittner R, Rosenfeld M, Redding G, Goss C . Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2010; 46(4):393-400. DOI: 10.1002/ppul.21374. View

Sawicki G, McKone E, Pasta D, Millar S, Wagener J, Johnson C . Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015; 192(7):836-42. DOI: 10.1164/rccm.201503-0578OC. View

Laguna T, Reilly C, Williams C, Welchlin C, Wendt C . Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation. Pediatr Pulmonol. 2015; 50(9):869-77. PMC: 5553866. DOI: 10.1002/ppul.23225. View

Aittokallio T, Schwikowski B . Graph-based methods for analysing networks in cell biology. Brief Bioinform. 2006; 7(3):243-55. DOI: 10.1093/bib/bbl022. View

Melnik A, Vazquez-Baeza Y, Aksenov A, Hyde E, McAvoy A, Wang M . Molecular and Microbial Microenvironments in Chronically Diseased Lungs Associated with Cystic Fibrosis. mSystems. 2019; 4(5). PMC: 6759567. DOI: 10.1128/mSystems.00375-19. View

Goss C, Burns J . Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 2007; 62(4):360-7. PMC: 2092469. DOI: 10.1136/thx.2006.060889. View

10.

Jiang K, Poppenberg K, Wong L, Chen Y, Borowitz D, Goetz D . RNA sequencing data from neutrophils of patients with cystic fibrosis reveals potential for developing biomarkers for pulmonary exacerbations. J Cyst Fibros. 2018; 18(2):194-202. PMC: 6309595. DOI: 10.1016/j.jcf.2018.05.014. View

11.

Charrier C, Rodger C, Robertson J, Kowalczuk A, Shand N, Fraser-Pitt D . Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis. Orphanet J Rare Dis. 2014; 9:189. PMC: 4260250. DOI: 10.1186/s13023-014-0189-2. View

12.

Keating D, Marigowda G, Burr L, Daines C, Mall M, McKone E . VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018; 379(17):1612-1620. PMC: 6289290. DOI: 10.1056/NEJMoa1807120. View

13.

Quinn R, Phelan V, Whiteson K, Garg N, Bailey B, Lim Y . Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome. ISME J. 2015; 10(6):1483-98. PMC: 5029181. DOI: 10.1038/ismej.2015.207. View

14.

Ferrari E, Monzani R, Villella V, Esposito S, Saluzzo F, Rossin F . Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation. Cell Death Dis. 2017; 8(1):e2544. PMC: 5386380. DOI: 10.1038/cddis.2016.476. View

15.

Saavedra M, Quon B, Faino A, Caceres S, Poch K, Sanders L . Whole Blood Gene Expression Profiling Predicts Severe Morbidity and Mortality in Cystic Fibrosis: A 5-Year Follow-Up Study. Ann Am Thorac Soc. 2018; 15(5):589-598. DOI: 10.1513/AnnalsATS.201707-527OC. View

16.

Stachowiak Z, Wojsyk-Banaszak I, Jonczyk-Potoczna K, Narozna B, Langwinski W, Kycler Z . MiRNA Expression Profile in the Airways is Altered during Pulmonary Exacerbation in Children with Cystic Fibrosis-A Preliminary Report. J Clin Med. 2020; 9(6). PMC: 7356328. DOI: 10.3390/jcm9061887. View

17.

Wisniewski B, Shrestha C, Zhang S, Thompson R, Gross M, Groner J . Metabolomics profiling of tobacco exposure in children with cystic fibrosis. J Cyst Fibros. 2020; 19(5):791-800. PMC: 7492400. DOI: 10.1016/j.jcf.2020.05.003. View

18.

Kopp B, Thompson R, Kim J, Konstan R, Diaz A, Smith B . Secondhand smoke alters arachidonic acid metabolism and inflammation in infants and children with cystic fibrosis. Thorax. 2019; 74(3):237-246. PMC: 7642975. DOI: 10.1136/thoraxjnl-2018-211845. View

19.

Ramsey K, Schultz A, Stick S . Biomarkers in Paediatric Cystic Fibrosis Lung Disease. Paediatr Respir Rev. 2015; 16(4):213-8. DOI: 10.1016/j.prrv.2015.05.004. View

20.

Anstead M, Saiman L, Mayer-Hamblett N, Lands L, Kloster M, Goss C . Pulmonary exacerbations in CF patients with early lung disease. J Cyst Fibros. 2013; 13(1):74-9. DOI: 10.1016/j.jcf.2013.07.006. View